1. Cooper N, Kruse A, Kruse C, et al. Immune thrombocytopenia (ITP) World Impact Survey (iWISh): patient and physician perceptions of diagnosis, signs and symptoms, and treatment. Am J Hematol. 2021;96(2):188-198.
2. Kuter DJ, Gouia I, Cordoba M, et al. Clinical burden of illness in patients with persistent or chronic primary immune thrombocytopenia treated with advanced therapies in the United States. Poster presented at: American Society of Hematology Annual Meeting & Exposition; December 7-10, 2024; San Diego, CA.
3. Andreescu M. The link between immune thrombocytopenia and the cytokine profile: a bridge to new therapeutical targets. Front Hematol. 2023;2:1191178.
4. Qiao J, Liu Y, Li X, et al. Elevated expression of NLRP3 in patients with immune thrombocytopenia. Immunol Res. 2016;64(2):431-437.
5. Schifferli A, Cavalli F, Godeau B, et al. Understanding immune thrombocytopenia: looking out of the box. Front Med (Lausanne). 2021;8:613192.
6. McMillan R, Bussel JB, George JN, Lalla D, Nichol JL. Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. Am J Hematol. 2008;83(2):150-154.
7. Cooper N, Ghanima W. Immune thrombocytopenia. N Engl J Med. 2019;381(10):945-955.
8. Audia S, Bonnotte B. Emerging therapies in immune thrombocytopenia. J Clin Med. 2021;10(5):1004.
9. Kistangari G, McCrae KR. Immune thrombocytopenia. Hematol Oncol Clin North Am. 2013;27(3):495-520.
10. Piel-Julian M-L, Mahévas M, Germain J, et al. Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults. J Thromb Haemost. 2018;16(9):1830-1842.
11. Neunert C, Noroozi N, Norman G, et al. Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review. J Thromb Haemost. 2015;13(3):457-464.
12. Pietras NM, Gupta N, Justiz Vaillant AA, Pearson-Shaver AL. Immune Thrombocytopenia. In: StatPearls. Treasure Island (FL): StatPearls Publishing; May 5, 2024.
13. van Dijk WEM, Nap-van der Vlist MM, Knoop H, Schutgens REG. Possible targets to reduce fatigue in chronic immune thrombocytopenia patients - an explorative study. TH Open. 2022;6(4):e387-e395.
14. Kuter DJ, Khan U, Maruff P, Daak A. Cognitive impairment among patients with chronic immune thrombocytopenia. Br J Haematol. 2024;205(1):291-299.
15. Rodeghiero F, Michel M, Gernsheimer T, et al. Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group. Blood. 2013;121(14):2596-2606.
16. Zainal A, Salama A, Alweis R. Immune thrombocytopenic purpura. J Community Hosp Intern Med Perspect. 2019;9(1):59-61.
17. McGrath A, Barrett MJ. Petechiae. In: StatPearls. Treasure Island (FL): StatPearls Publishing; September 4, 2023.
18. Kayal L, Jayachandran S, Singh K. Idiopathic thrombocytopenic purpura. Contemp Clin Dent.2014;5(3):410-414.
19. Immune Thrombocytopenia. The National Organization for Rare Disorders (NORD). Updated July 12, 2022. Accessed May 9, 2025.
20. Madkhali MA. Recent advances in the management of immune thrombocytopenic purpura (ITP): a comprehensive review. Medicine (Baltimore). 2024;103(3):e36936.
21. Arnold DM. Bleeding complications in immune thrombocytopenia. Hematology Am Soc Hematol Educ Program. 2015;2015:237-242.
22. Pongsakul A, Daniel A, Lochala R, Martin DE. Intracerebral hemorrhage in a patient with newly diagnosed immune thrombocytopenic purpura precipitated by a viral illness. Cureus. 2024;16(3):e57284.
23. Diyora B, Purandare A, Devani K, Kale P, Shah V, Patankar R. Life-threatening intracerebral hemorrhage in adult with ITP: challenging entity. Asian J Neurosurg. 2023;18(2):391-395.
24. Rovó A, Cantoni N, Samii K, et al. Real-world impact of primary immune thrombocytopenia and treatment with thrombopoietin receptor agonists on quality of life based on patient-reported experience: results from a questionnaire conducted in Switzerland, Austria, and Belgium. PLoS One. 2022;17(4):e0267342.
25. Williamson DR, Albert M, Heels-Ansdell D, et al. Thrombocytopenia in critically ill patients receiving thromboprophylaxis: frequency, risk factors, and outcomes. Chest. 2013;144(4):1207-1215.
26. Kewan T, Gunaratne TN, Mushtaq K, et al. Outcomes and management of immune thrombocytopenia secondary to COVID-19: Cleveland clinic experience. Transfusion. 2021;61(7):2014-2018.
27. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386-2393.

Trombocitopenia Inmune Primaria (PTI)

Artículos

Descifrando la PTI

Vivir con PTI

Evaluación de la fatiga en pacientes con PTI